FCER1G

Summary

FCER1G (Fc epsilon receptor Ig, HGNC:3611) is a protein-coding gene on chromosome 1q23.3, encoding High affinity immunoglobulin epsilon receptor subunit gamma (P30273). Adapter protein containing an immunoreceptor tyrosine-based activation motif (ITAM) that transduces activation signals from various immunoreceptors.

The high affinity IgE receptor is a key molecule involved in allergic reactions. It is a tetramer composed of 1 alpha, 1 beta, and 2 gamma chains. The gamma chains are also subunits of other Fc receptors.

Source: NCBI Gene 2207 — RefSeq curated summary.

At a glance

• GWAS associations: 21
• Clinical variants (ClinVar): 16 total
• MANE Select transcript: NM_004106

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3611
Approved symbol	FCER1G
Name	Fc epsilon receptor Ig
Location	1q23.3
Locus type	gene with protein product
Status	Approved
Aliases	FcepsilonRIgamma
Ensembl gene	ENSG00000158869
Ensembl biotype	protein_coding
OMIM	147139
Entrez	2207

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000289902, ENST00000367992, ENST00000490414, ENST00000882697

RefSeq mRNA: 1 — MANE Select: NM_004106 NM_004106

CCDS: CCDS1225

Canonical transcript exons

ENST00000289902 — 5 exons

Exon	Start	End
ENSE00001041693	161217986	161218077
ENSE00001068321	161215295	161215370
ENSE00003480932	161218703	161218723
ENSE00003565129	161218881	161219245
ENSE00003609913	161218241	161218276

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 99.79.

FANTOM5 (CAGE): breadth broad, TPM avg 278.8084 / max 13061.0453, expressed in 580 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6218	278.8084	580

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	99.79	gold quality
mononuclear cell	CL:0000842	99.77	gold quality
leukocyte	CL:0000738	99.76	gold quality
granulocyte	CL:0000094	99.69	gold quality
right lung	UBERON:0002167	99.20	gold quality
upper lobe of left lung	UBERON:0008952	98.98	gold quality
blood	UBERON:0000178	98.97	gold quality
spleen	UBERON:0002106	98.93	gold quality
upper lobe of lung	UBERON:0008948	98.62	gold quality
bone marrow	UBERON:0002371	98.35	gold quality
bone marrow cell	CL:0002092	98.11	gold quality
right coronary artery	UBERON:0001625	97.97	gold quality
gall bladder	UBERON:0002110	97.75	gold quality
rectum	UBERON:0001052	97.55	gold quality
descending thoracic aorta	UBERON:0002345	97.38	gold quality
omental fat pad	UBERON:0010414	97.31	gold quality
peritoneum	UBERON:0002358	97.22	gold quality
left coronary artery	UBERON:0001626	96.98	gold quality
mucosa of stomach	UBERON:0001199	96.85	gold quality
right adrenal gland cortex	UBERON:0035827	96.74	gold quality
thoracic aorta	UBERON:0001515	96.72	gold quality
right adrenal gland	UBERON:0001233	96.62	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.62	gold quality
ascending aorta	UBERON:0001496	96.60	gold quality
vermiform appendix	UBERON:0001154	96.52	gold quality
left adrenal gland	UBERON:0001234	96.52	gold quality
left adrenal gland cortex	UBERON:0035825	96.48	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.46	gold quality
trabecular bone tissue	UBERON:0002483	96.43	gold quality
lymph node	UBERON:0000029	96.02	gold quality

Single-cell (SCXA)

Detected in 52 experiment(s), a significant marker in 49.

Experiment	Marker?	Max mean expression
E-MTAB-8495	yes	4690.42
E-GEOD-135922	yes	4369.24
E-HCAD-15	yes	4144.79
E-MTAB-6308	yes	4113.41
E-CURD-55	yes	4093.06
E-MTAB-8410	yes	3504.67
E-MTAB-8142	yes	3474.71
E-GEOD-149689	yes	3341.43
E-CURD-126	yes	3257.22
E-GEOD-139324	yes	3213.09
E-HCAD-1	yes	3112.87
E-CURD-88	yes	3017.18
E-CURD-122	yes	2924.58
E-HCAD-4	yes	2746.17
E-CURD-46	yes	2564.51

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, EGR1, ELF1, ESR1, FOS, GATA1, GATA2, HES1, NCOA3, RBPJ, SP1, SPI1, SPIB, SPIC, SSRP1, STAT6, TBXT, USF1, USF2, ZFPM1

miRNA regulators (miRDB)

31 targeting FCER1G, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-1197	99.70	67.75	1027
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-302D-5P	99.50	69.34	1863
HSA-MIR-302B-5P	99.50	69.49	1857
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-4786-3P	99.36	68.35	1390
HSA-MIR-4721	99.26	66.05	818
HSA-MIR-4528	99.18	69.77	1936
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-3135B	98.61	65.33	1470
HSA-MIR-4303	98.01	68.13	2304
HSA-MIR-6511B-5P	97.98	65.64	823
HSA-MIR-6811-5P	97.98	64.96	848
HSA-MIR-5189-3P	97.52	66.33	487
HSA-MIR-4259	95.68	65.25	582
HSA-MIR-4693-3P	95.23	65.92	735
HSA-MIR-4694-5P	94.62	65.39	532

Literature-anchored findings (GeneRIF, showing 28)

• Conservation of FcepsilonRI gamma chain coding region in normals and in SLE patients. (PMID:11898918)
• FCGR3B quantification confirms the idea of the HNA-1c antigen to be inherited not only linked to HNA-1a, but also to be passed down on its own. (PMID:12366784)
• Overexpression of the Fc epsilon RI gamma chain in normal T cells associates with TCR/CD3 complex, contributes to altered T cell signaling, and down-regulates the endogenous TCR zeta-chain expression in human T cells. (PMID:12626537)
• evidence that FcepsilonRI-gamma (gamma) associates with 2DL4 to promote surface expression and provide signal transducing function. (PMID:15778339)
• Data suggest that by associating with Fc epsilon RI gamma, BDCA2 activates a novel BCR-like signaling pathway to regulate the immune functions of plasmacytoid dendritic cells. (PMID:17850179)
• The activating functions of KIR2DL4 killer receptor in natural killer (NK) cells are compartmentalized into distinct structural modules through transmembrane association with the Fc epsilon RI-gamma (FCERIG) receptor. (PMID:18292514)
• Elf-1 in combination with Sp1 and GABP reduced FcRgamma promoter activity. (PMID:18378679)
• reduced expression in histamin non-releaser basophils (PMID:19362683)
• No associations with total and specific IgE levels as well as allergic sensitization were seen for FCER1B and FCER1G (PMID:20028371)
• Data suggest a contribution of Fc epsilonRI alpha and gamma chains either to immunosurveillance or pathophysiology of the intestinal epithelium. (PMID:20126404)
• Demethylation of specific regulatory elements within the FCER1G locus contributes to FcepsilonRI overexpression on monocytes from patients with atopic dermatitis. (PMID:22150093)
• Altered expression of the TCR signaling related genes CD3 and FcepsilonRIgamma in patients with aplastic anemia. (PMID:22401598)
• There was loss of the negative correlation in the expression levels of CD3eta and FcepsilonRIgamma genes in CLL patients. (PMID:22664044)
• CD2-associated adaptor protein (CD2AP) positively regulates blood dendritic cell antigen 2 (BDCA2)/FcepsilonR1gamma signaling by forming a complex with SH2 domain-containing inositol 5’-phosphatase (SHIP)1 to inhibit the E3 ubiquitin ligase Cbl. (PMID:22706086)
• High expression of FCER1G is associated with chronic myeloid leukemia. (PMID:23228155)
• Studies indicate that in response to stimulation with antigen, PHB1 translocated to plasma membrane lipid rafts to form a ternary complex with the high-affinity IgE receptor FcepsilonRIgamma and the nonreceptor tyrosine kinase Syk. (PMID:24023253)
• Data indicate that the decreasing trend in the expression level of TCRzeta chain, ZAP-70 kinase and epsilon Fc Receptors FcvarepsilonRIgamma was significantly associated with disease progression. (PMID:25513989)
• FcgammaR-mediated Syk activation leads to NLRP3 inflammasome-dependent IL-1beta production in macrophages and suggests that an Nlrp3- and IL-1R-dependent process contributes to the IgA response important for protection against Francisella tularensis LVS. (PMID:27365531)
• mass spectrometry of WT human FcRgamma from receptor-stimulated cells shows consistent preferential phosphorylation of the serine residue at position 51. (PMID:27630214)
• FCER1G was identified and validated in association with ccRCC progression and prognosis, which might improve the prognosis by influencing immune-related pathways (PMID:29209141)
• Phenotypic and Functional Analysis of Human NK Cell Subpopulations According to the Expression of FcepsilonRIgamma and NKG2C. (PMID:31867015)
• Identification of TYROBP and FCER1G as Key Genes with Prognostic Value in Clear Cell Renal Cell Carcinoma by Bioinformatics Analysis. (PMID:33786672)
• FCER1G and PTGS2 Serve as Potential Diagnostic Biomarkers of Acute Myocardial Infarction Based on Integrated Bioinformatics Analyses. (PMID:34115526)
• The role of SPI1-TYROBP-FCER1G network in oncogenesis and prognosis of osteosarcoma, and its association with immune infiltration. (PMID:35078433)
• Fc Fragment of IgE Receptor Ig (FCER1G) acts as a key gene involved in cancer immune infiltration and tumour microenvironment. (PMID:36054819)
• Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcepsilonRIgamma expression. (PMID:36066491)
• Identification of FCER1G as a key gene in multiple myeloma based on weighted gene co-expression network analysis. (PMID:37170758)
• Identification of FCER1G as a cyclosporin A plus corticosteroid sensitization gene in female patients with Vogt-Koyanagi-Harada disease. (PMID:37821074)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cd247l	ENSDARG00000077240
mus_musculus	Fcer1g	ENSMUSG00000058715
rattus_norvegicus	Fcer1g	ENSRNOG00000024159

Protein

Protein identifiers

High affinity immunoglobulin epsilon receptor subunit gamma — P30273 (reviewed: P30273)

Alternative names: Fc receptor gamma-chain, Fc-epsilon RI-gamma, IgE Fc receptor subunit gamma

All UniProt accessions (2): P30273, A6NCQ8

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein containing an immunoreceptor tyrosine-based activation motif (ITAM) that transduces activation signals from various immunoreceptors. As a component of the high-affinity immunoglobulin E (IgE) receptor, mediates allergic inflammatory signaling in mast cells. As a constitutive component of interleukin-3 receptor complex, selectively mediates interleukin 4/IL4 production by basophils, priming T-cells toward effector T-helper 2 subset. Associates with pattern recognition receptors CLEC4D and CLEC4E to form a functional signaling complex in myeloid cells. Binding of mycobacterial trehalose 6,6’-dimycolate (TDM) to this receptor complex leads to phosphorylation of ITAM, triggering activation of SYK, CARD9 and NF-kappa-B, consequently driving maturation of antigen-presenting cells and shaping antigen-specific priming of T-cells toward effector T-helper 1 and T-helper 17 cell subtypes. May function cooperatively with other activating receptors. Functionally linked to integrin beta-2/ITGB2-mediated neutrophil activation. Also involved in integrin alpha-2/ITGA2-mediated platelet activation.

Subunit / interactions. IgE Fc receptor is a tetramer of an alpha chain, a beta chain, and two disulfide-linked gamma chains. Associates with FCGR1A; forms a functional signaling complex. The signaling subunit of immunoglobulin gamma (IgG) Fc receptor complex. As a homodimer or a heterodimer of CD247 and FCER1G, associates with the ligand binding subunit FCGR3A to form a functional receptor complex. Associated with CLEC6A. Interacts with CLEC4E. Interacts (via ITAM domain) with SYK (via SH2 domains); activates SYK, enabling integrin-mediated activation of neutrophils and macrophages. Interacts with CSF2RB and recruits SYK in response to IL3 stimulation; this interaction is direct. Interacts with CD300LH; the interaction may be indirect. Interacts with CD300LD. Interacts with TARM1.

Subcellular location. Cell membrane.

Similarity. Belongs to the CD3Z/FCER1G family.

RefSeq proteins (1): NP_004097* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003110	Phos_immunorcpt_sig_ITAM	Repeat
IPR021663	CD3_zeta/IgE_Fc_rcpt_gamma	Family
IPR042340	FCER1G	Family

Pfam: PF02189, PF11628

UniProt features (12 total): modified residue 4, topological domain 2, signal peptide 1, chain 1, disulfide bond 1, helix 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
7Q5T	X-RAY DIFFRACTION	2.2
8YWA	ELECTRON MICROSCOPY	3.14
8YVU	ELECTRON MICROSCOPY	3.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P30273-F1	72.28	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 65, 69, 76, 78

Disulfide bonds (1): 25

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-114604	GPVI-mediated activation cascade
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-2454202	Fc epsilon receptor (FCERI) signaling
R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-2871796	FCERI mediated MAPK activation
R-HSA-2871809	FCERI mediated Ca+2 mobilization
R-HSA-2871837	FCERI mediated NF-kB activation
R-HSA-5621480	Dectin-2 family
R-HSA-6798695	Neutrophil degranulation
R-HSA-75892	Platelet Adhesion to exposed collagen

MSigDB gene sets: 537 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_CELLULAR_RESPONSE_TO_LIPOPROTEIN_PARTICLE_STIMULUS, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, DAVIES_MULTIPLE_MYELOMA_VS_MGUS_DN, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION_OF_PEPTIDE_OR_POLYSACCHARIDE_ANTIGEN_VIA_MHC_CLASS_II, WALLACE_PROSTATE_CANCER_RACE_UP, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_INFLAMMATORY_RESPONSE_TO_ANTIGENIC_STIMULUS, GOBP_POSITIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, MCLACHLAN_DENTAL_CARIES_UP, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_CELL_CHEMOTAXIS

GO Biological Process (40): positive regulation of type IIa hypersensitivity (GO:0001798), positive regulation of type III hypersensitivity (GO:0001805), positive regulation of type I hypersensitivity (GO:0001812), neutrophil activation involved in immune response (GO:0002283), T cell differentiation involved in immune response (GO:0002292), Fc receptor mediated stimulatory signaling pathway (GO:0002431), serotonin secretion by platelet (GO:0002554), phagocytosis, engulfment (GO:0006911), integrin-mediated signaling pathway (GO:0007229), regulation of platelet activation (GO:0010543), immunoglobulin mediated immune response (GO:0016064), antigen processing and presentation of exogenous peptide antigen via MHC class II (GO:0019886), osteoclast differentiation (GO:0030316), neutrophil chemotaxis (GO:0030593), receptor internalization (GO:0031623), positive regulation of interleukin-10 production (GO:0032733), positive regulation of interleukin-4 production (GO:0032753), positive regulation of interleukin-6 production (GO:0032755), positive regulation of tumor necrosis factor production (GO:0032760), positive regulation of mast cell cytokine production (GO:0032765), mast cell apoptotic process (GO:0033024), negative regulation of mast cell apoptotic process (GO:0033026), Fc-gamma receptor signaling pathway (GO:0038094), Fc-epsilon receptor signaling pathway (GO:0038095), interleukin-3-mediated signaling pathway (GO:0038156), antigen processing and presentation of exogenous peptide antigen via MHC class I (GO:0042590), defense response to bacterium (GO:0042742), mast cell degranulation (GO:0043303), positive regulation of mast cell degranulation (GO:0043306), innate immune response (GO:0045087), positive regulation of phagocytosis (GO:0050766), cellular response to low-density lipoprotein particle stimulus (GO:0071404), protein localization to plasma membrane (GO:0072659), positive regulation of protein localization to cell surface (GO:2000010), immune system process (GO:0002376), signal transduction (GO:0007165), cell surface receptor signaling pathway (GO:0007166), mast cell activation (GO:0045576), regulation of immune response (GO:0050776), positive regulation of immune response (GO:0050778)

GO Molecular Function (7): IgE receptor activity (GO:0019767), IgE binding (GO:0019863), IgG binding (GO:0019864), identical protein binding (GO:0042802), protein homodimerization activity (GO:0042803), transmembrane signaling receptor activity (GO:0004888), protein binding (GO:0005515)

GO Cellular Component (9): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), Fc-epsilon receptor I complex (GO:0032998), Fc-gamma receptor III complex (GO:0033001), tertiary granule membrane (GO:0070821), ficolin-1-rich granule membrane (GO:0101003), membrane (GO:0016020), plasma membrane protein complex (GO:0098797)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Fc epsilon receptor (FCERI) signaling	4
Hemostasis	2
Innate Immune System	2
Platelet activation, signaling and aggregation	1
C-type lectin receptors (CLRs)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of cytokine production	3
positive regulation of hypersensitivity	2
positive regulation of immunoglobulin mediated immune response	2
immune response	2
immunoglobulin binding	2
plasma membrane	2
cellular anatomical structure	2
Fc receptor complex	2
secretory granule membrane	2
tertiary granule	2
type IIa hypersensitivity	1
regulation of type IIa hypersensitivity	1
positive regulation of type II hypersensitivity	1
type III hypersensitivity	1
regulation of type III hypersensitivity	1
positive regulation of myeloid leukocyte mediated immunity	1
regulation of type I hypersensitivity	1
type I hypersensitivity	1
myeloid cell activation involved in immune response	1
neutrophil activation	1
T cell activation involved in immune response	1
T cell differentiation	1
immune response-activating cell surface receptor signaling pathway	1
serotonin secretion involved in inflammatory response	1
platelet degranulation	1
establishment of localization in cell	1
exocytic process	1
phagocytosis	1
plasma membrane invagination	1
cell surface receptor signaling pathway	1
platelet activation	1
regulation of cell activation	1
B cell mediated immunity	1
antigen processing and presentation of exogenous peptide antigen	1
antigen processing and presentation of peptide antigen via MHC class II	1
myeloid leukocyte differentiation	1
granulocyte chemotaxis	1
neutrophil migration	1
receptor-mediated endocytosis	1
interleukin-10 production	1

Protein interactions and networks

STRING

2348 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FCER1G	GP6	Q9HCN6	999
FCER1G	SYK	P43405	998
FCER1G	FCGR3A	P08637	997
FCER1G	FCGR3B	O75015	996
FCER1G	NCR1	O76036	995
FCER1G	CLEC6A	Q6EIG7	994
FCER1G	CLEC4E	Q9ULY5	994
FCER1G	OSCAR	Q8IYS5	992
FCER1G	TREM2	Q9NZC2	990
FCER1G	NCR3	O14931	989
FCER1G	FCAR	P24071	977
FCER1G	FCER1A	P12319	975
FCER1G	FCGR1A	P12314	970
FCER1G	TYROBP	O43914	964
FCER1G	LILRA4	P59901	937

IntAct

19 interactions, top by confidence:

A	B	Type	Score
FCER1G	CD300C	psi-mi:“MI:0915”(physical association)	0.590
FCGR1A	FCER1G	psi-mi:“MI:0407”(direct interaction)	0.560
SYK	FCER1G	psi-mi:“MI:0915”(physical association)	0.560
SYK	FCER1G	psi-mi:“MI:0914”(association)	0.560
NCR1	FCER1G	psi-mi:“MI:0915”(physical association)	0.400
CLEC4C	FCER1G	psi-mi:“MI:0915”(physical association)	0.400
FCER1G	CLEC4C	psi-mi:“MI:0915”(physical association)	0.400
FCER1G	CD300LD	psi-mi:“MI:0915”(physical association)	0.400
FCER1G	GP6	psi-mi:“MI:0915”(physical association)	0.400
FCER1G	BTK	psi-mi:“MI:0915”(physical association)	0.400
FCER1G		psi-mi:“MI:0915”(physical association)	0.370
FCER1G	rep	psi-mi:“MI:0915”(physical association)	0.370
SLC15A4	ESYT2	psi-mi:“MI:0914”(association)	0.350
MAPT	SEPTIN8	psi-mi:“MI:0914”(association)	0.350
FCER1G		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (90): FCAR (Affinity Capture-Western), FCER1G (Affinity Capture-Western), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid), FCER1G (Two-hybrid)

ESM2 similar proteins: O02757, O97797, P07766, P09693, P0CAN6, P11911, P11912, P11942, P18438, P18439, P20411, P20491, P22646, P27597, P29328, P30273, P31043, P40259, P40293, P42069, Q07249, Q14802, Q1XF11, Q28071, Q28072, Q28073, Q28074, Q3MHZ5, Q4R566, Q5PXD3, Q5R1Q1, Q5RB29, Q61835, Q64159, Q6X9T7, Q764N2, Q7YRN2, Q8SPW1, Q8WNQ9, Q91XV6

Diamond homologs: P20411, P20491, P20963, P24161, P29329, P30273, Q07249, Q8SPW1, Q9BDR7, Q9TUF8, Q9XSJ9, Q9XSZ6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
FCER1G	“form complex”	FCER1G/FCER1G	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

16 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	8
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

521 predictions. Top by Δscore:

Variant	Effect	Δscore
1:161218699:GCAG:G	acceptor_loss	1.0000
1:161218700:CA:C	acceptor_loss	1.0000
1:161218701:A:AG	acceptor_gain	1.0000
1:161218701:A:T	acceptor_loss	1.0000
1:161218702:G:GG	acceptor_gain	1.0000
1:161218702:GAA:G	acceptor_gain	1.0000
1:161215367:GCAG:G	donor_gain	0.9900
1:161215371:GT:G	donor_loss	0.9900
1:161217929:T:TA	acceptor_gain	0.9900
1:161217984:A:AG	acceptor_gain	0.9900
1:161217984:AGC:A	acceptor_gain	0.9900
1:161217985:G:GG	acceptor_gain	0.9900
1:161217985:GCG:G	acceptor_gain	0.9900
1:161218073:TGAAG:T	donor_loss	0.9900
1:161218074:GAAGG:G	donor_loss	0.9900
1:161218076:AG:A	donor_loss	0.9900
1:161218235:TTCCA:T	acceptor_loss	0.9900
1:161218236:TCCAG:T	acceptor_loss	0.9900
1:161218237:CCAGA:C	acceptor_loss	0.9900
1:161218238:CAGAT:C	acceptor_loss	0.9900
1:161218239:A:AC	acceptor_loss	0.9900
1:161218239:A:AG	acceptor_gain	0.9900
1:161218240:G:GA	acceptor_loss	0.9900
1:161218240:G:GG	acceptor_gain	0.9900
1:161218692:T:TA	acceptor_gain	0.9900
1:161218698:T:TA	acceptor_gain	0.9900
1:161218702:GA:G	acceptor_gain	0.9900
1:161218702:GAAAT:G	acceptor_gain	0.9900
1:161218724:G:GA	donor_loss	0.9900
1:161218724:G:GG	donor_gain	0.9900

AlphaMissense

533 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:161218043:G:A	G36E	0.997
1:161218042:G:A	G36R	0.996
1:161218042:G:C	G36R	0.996
1:161218031:T:A	L32Q	0.994
1:161218052:T:A	L39H	0.994
1:161218022:A:C	D29A	0.993
1:161218021:G:C	D29H	0.992
1:161218021:G:A	D29N	0.991
1:161218023:T:A	D29E	0.991
1:161218023:T:G	D29E	0.991
1:161218052:T:C	L39P	0.991
1:161218022:A:T	D29V	0.990
1:161218066:T:C	C44R	0.990
1:161218022:A:G	D29G	0.989
1:161218031:T:C	L32P	0.989
1:161218063:T:G	Y43D	0.989
1:161218052:T:G	L39R	0.987
1:161218009:T:C	C25R	0.986
1:161218019:T:C	L28P	0.985
1:161218024:G:C	A30P	0.985
1:161218031:T:G	L32R	0.984
1:161218073:T:C	L46P	0.984
1:161218049:T:A	V38D	0.982
1:161218070:G:C	R45P	0.982
1:161218010:G:A	C25Y	0.981
1:161218019:T:A	L28Q	0.981
1:161218077:G:C	K47N	0.980
1:161218077:G:T	K47N	0.980
1:161218908:T:C	Y76H	0.980
1:161218025:C:A	A30D	0.977

dbSNP variants (sampled 300 via entrez): RS1000176161 (1:161216045 A>G), RS1000341683 (1:161216813 G>C), RS1000534798 (1:161219152 C>T), RS1000696527 (1:161218415 A>C,G), RS1000830137 (1:161219486 G>T), RS1001552901 (1:161215784 G>T), RS1001994035 (1:161214883 A>C,G), RS1002204153 (1:161215041 T>G), RS1002341847 (1:161214623 T>C), RS1003787467 (1:161218513 T>C), RS1004008352 (1:161217446 A>G), RS1004124370 (1:161217190 T>C,G), RS1005789364 (1:161215342 G>A,T), RS1005795592 (1:161215828 G>A), RS1005847420 (1:161215998 G>A,T)

Disease associations

OMIM: gene MIM:147139 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

21 associations (top):

Study	Trait	p-value
GCST003990_19	Allergy	1.000000e-09
GCST004303_3	Aggressive periodontitis	4.000000e-06
GCST004599_254	Mean platelet volume	2.000000e-13
GCST004616_116	Platelet distribution width	1.000000e-16
GCST005038_11	Allergic disease (asthma, hay fever or eczema)	1.000000e-11
GCST006409_33	Allergic rhinitis	6.000000e-19
GCST007797_50	Asthma onset (childhood vs adult)	1.000000e-06
GCST007798_9	Asthma	9.000000e-12
GCST007800_18	Asthma (childhood onset)	3.000000e-32
GCST008916_64	Asthma	2.000000e-08
GCST009719_20	Allergic rhinitis	4.000000e-10
GCST009720_86	Asthma	1.000000e-09
GCST010042_101	Asthma	4.000000e-12
GCST010043_86	Asthma	7.000000e-16
GCST90002395_538	Mean platelet volume	6.000000e-40
GCST90002395_539	Mean platelet volume	2.000000e-11
GCST90002398_498	Neutrophil count	2.000000e-12
GCST90002401_365	Platelet distribution width	1.000000e-47
GCST90002401_366	Platelet distribution width	3.000000e-11
GCST90002402_500	Platelet count	2.000000e-10
GCST90002407_9	White blood cell count	2.000000e-11

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007984	platelet component distribution width
EFO:0004847	age at onset
EFO:0004833	neutrophil count
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs11587213	Toxicity	3	aspirin	Asthma

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs11587213	FCER1G	3	4.50	1	aspirin

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Fc epsilon receptors

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aspirin	decreases expression, affects response to substance	3
Tretinoin	increases expression	3
Air Pollutants	affects expression, increases abundance, decreases expression	2
Nickel	increases expression	2
Ozone	affects expression, increases abundance, decreases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
testosterone enanthate	affects expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases methylation	1
sodium arsenite	affects splicing, decreases expression	1
convulxin	increases reaction, increases phosphorylation, affects binding, decreases reaction	1
tamibarotene	increases expression	1
nilotinib	affects cotreatment, affects expression	1
fenbuconazole	increases expression	1
Decitabine	increases expression	1
Arsenic Trioxide	affects cotreatment, affects expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	affects expression, decreases expression, affects cotreatment	1
Calcitriol	decreases expression	1
Cisplatin	increases expression	1
Diethylhexyl Phthalate	increases expression	1
Lipopolysaccharides	affects cotreatment, affects expression, increases expression	1
Methotrexate	decreases expression	1
Quercetin	increases expression	1
Valproic Acid	decreases expression	1
Citalopram	affects binding, decreases reaction, increases reaction	1
Asbestos, Serpentine	decreases expression	1
Antirheumatic Agents	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

13 cell lines: 7 cancer cell line, 5 spontaneously immortalized cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1F83	TZM-bl/FcalphaR	Cancer cell line	Female
CVCL_C4MP	RBL SX-38	Cancer cell line
CVCL_D5HB	Abcam THP-1 FCER1G KO	Cancer cell line	Male
CVCL_E1A9	Ubigene NK-92 FCER1G KO	Cancer cell line	Male
CVCL_E4J6	Genomeditech Jurkat H_CLEC4C(BDCA2) Reporter	Cancer cell line	Male
CVCL_E5I6	CHO-K1/CD16A 158V	Spontaneously immortalized cell line	Female
CVCL_E5I7	CHO-K1/CD64	Spontaneously immortalized cell line	Female
CVCL_E5IG	CHO-K1/BDCA2 and FcER1G	Spontaneously immortalized cell line	Female
CVCL_E6Q2	Genomeditech CHO-K1 H_CLEC4C(BDCA2)+FCER1G	Spontaneously immortalized cell line	Female
CVCL_E6TS	Genomeditech HEK-293 H_CLEC4C(BDCA2)+FCER1G	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.